Best Therapy for Patients With Neuroendocrine Tumors
Study design:
Prospective observational study comparing ablative measures as TACE or SIRT with surgery/RFA
and with peptide receptor radio-therapy in patients with advanced well-differentiated
neuroendocrine tumors with lymph node or distant metastases (N1, M1) Prospective evaluation
Primary end points: time to progression Secondary end points: survival, quality of life
(EORTC-QLQ30), weight, time of hospitalization, Karnofsky index) Non-randomized cohort study
Number of patients needed in all groups: 70 per group, 210 overall Evaluation of response to
therapy every 3-6 months by imaging, clinical status, weight, quality of life,
Karnofsky-index Cross-over allowed if therapy changes
Observational
Observational Model: Cohort, Time Perspective: Prospective
progression-free survival
2 years
No
Dieter Hörsch, MD
Principal Investigator
Zentralklinik Bad Berka GmbH
Germany: Ministry of Health
ZBB-NET-1
NCT00815620
November 2008
November 2012
Name | Location |
---|